SciBase’s new instrument Nevisense View which combines patented impedance measurement (EIS) for early detection of malignant melanoma with visual information from digital dermoscopy,  has left SciBase for delivery to Belgium.

The new instrument Nevisense View integrates images from digital dermoscopy with Nevisense’s EIS-technology.  The result is that all information from a skin examination is gathered in the same instrument, thus improving clinic workflow. To be able to track the development of a suspicious lesion, with the help of both EIS-values and images, helps prevent unnecessary excision of healthy lesions and minimises the risk of missing malignant melanoma.

“A new Australian study, presented in August of this year, showed that the utilisation of EIS can reduce the number of cases that need to undergo sequential digital dermoscopy monitoring by almost half while also detecting most malignant melanomas three months earlier than sequential digital dermoscopy alone.  The combination of digital dermoscopy and our unique EIS-measurement in the same instrument is therefore of both significant clinical benefit and can also potentially deliver significant health economic savings,” says Simon Grant, CEO of SciBase.